Search

The coagulation defects of the blood of 30 patients after six months of dicumarol therapy have been studied. A preparation of brain or soybean phospholipids corrected the abnormal coagulation time and the thrombin generation test of patients on long-term dicumarol therapy. The deficiency in thromboplastin generation of these patients was not corrected.

Seventy-eight patients were given long-term dicumarol therapy after one or more attacks of myocardial infarction to see whether recurrent attacks could be warded off. Encouraging results ensued over periods up to five years. Protocols of 12 fatal cases are given, only 4 of whom had recurrent acute coronary thrombosis. Hemorrhagic complications met with are analyzed. Ambulatory treatment is shown to be feasible if patients are painstakingly followed.